Hangzhou Tigermed Consulting Co., Ltd.

Hangzhou Tigermed Consulting Co., Ltd. is a prominent Contract Research Organization (CRO) based in China, specializing in providing comprehensive clinical trial services. Established in 2004 and listed on the Shenzhen Stock Exchange in 2012, Tigermed is dedicated to enhancing the efficiency and quality of medical product development. The company is headquartered in Hangzhou and operates through a network of 33 subsidiaries and 60 offices across China, along with 10 international offices in regions including the USA, Canada, and Australia, employing over 3,200 staff members. Tigermed's primary business lines encompass clinical trial technical services, clinical trial-related services, and laboratory services. The company has established a robust project management system and maintains strong relationships with study sites, enabling efficient execution of clinical trials. Tigermed's Biometrics division offers data management and biostatistics services, while its Site Management Organization provides tailored on-site management for clinical operations. With a focus on innovation, Tigermed has been involved in numerous drug development projects, supporting both local and global clients in the pharmaceutical industry.

During the reporting period, the company's main business income was 3.6703578 billion yuan, compared with 3.5528401 billion yuan in the same period last year, an increase of 3.31% over the same period last year; the net profit belonging to shareholders of listed companies was 1.388337 billion yuan, compared with 11.920 million yuan in the same period last year, up 16.47% over the same period last year; the net profit belonging to shareholders of listed companies after deducting non-recurrent profits and losses was 79,347.44 million yuan, an increase of 2.86% over the same period last year. During the reporting period, the company's main business income was 3.6703578 billion yuan, compared with 3.5528401 billion yuan in the same period last year, an increase of 3.31% over the same period last year, including 2.1033503 billion yuan in clinical trial technical services, compared with the same period last year. 2.1721459 billion yuan, down 3.17% from the same period last year; revenue from clinical trial-related services and laboratory services was 1.5670075 billion yuan, compared with 1.3806942 billion yuan in the same period last year, an increase of 13.49% over the same period last year. (1) Technical services for clinical trials. During the reporting period, the revenue from technical services in clinical trials was 2.1033503 billion yuan, compared with 2.1721459 billion yuan in the same period last year, a decrease of 3.17% over the same period last year, mainly due to the decrease in clinical trials of specific vaccine projects carried out by the company during the reporting period. Excluding these items, the revenue from technical services in clinical trials increased by more than 40% compared with the same period last year. As of June 30, 2023, the company's ongoing drug clinical research projects increased from 607 projects on June 30, 2022 and 680 projects on December 31, 2022 to 772 projects. As of June 30, 2023, the company has 503 drug clinical research projects in China and 269 projects abroad, of which 207 projects are conducting single-region clinical trials abroad (including South Korea, Australia and the United States). There are 62 projects in multi-regional clinical trials. (2) Clinical trial related services and laboratory services. The income of clinical trial-related services and laboratory services was 1.5670075 billion yuan, compared with 1.3806942 billion yuan in the same period last year, an increase of 13.49 percent over the same period last year. During the reporting period, the company's data management and statistical analysis services obtained more new customers at home and abroad, and the number of global customers increased to 296 from 208 in the same period last year. By the end of the reporting period, the company had 859 ongoing projects, of which 553 were implemented by domestic teams and 306 by overseas teams.